SUBSCRIBE

Issue Details

QIB

NIB



IPO Note 23rd June 2025

Company Overview

Ellenbarrie Industrial Gases Ltd. (EIG), one of the oldest operating industrial gases companies in India, manufactures and supplies industrial gases including oxygen, carbon dioxide, acetylene, nitrogen, helium, hydrogen, argon, and nitrous oxide, as well as dry ice, synthetic air, fire-fighting gases, medical oxygen, liquid petroleum gas, welding mixtures, and specialty gases catering to a diverse set of end-use industries. EIG is a key player in the industrial gases market in East and South India, holding a leading position in West Bengal, Andhra Pradesh, and Telangana in terms of installed manufacturing capacity. The company provides project engineering services, leveraging its extensive technical expertise to design, engineer, supply, install, and commission tonnage air separation units (ASUs) and related projects on a turnkey basis for customers across various sectors. The company also offers turnkey solutions involving medical gas pipeline systems, where it assists healthcare facilities in designing, installing, commissioning, operating, and maintaining these systems. In addition, it supplies essential medical equipment to healthcare facilities, including anaesthesia workstations, spirometers, ventilators, sterilizers, bedside monitors, and lung diffusion testing machines. The company operates across multiple modalities of supply, namely onsite, bulk, and packaged, whereby it distributes its products through pipelines connected to the customers, cryogenic tankers, and cylinders. It has one of the most extensive distribution networks in the country, ranking third in terms of transport tankers, cylinders, and customer installations. EIG's portfolio of industrial and medical gases plays a critical role in serving public and private clients across various industries, including steel, pharmaceuticals and chemicals, healthcare, engineering and infrastructure, railways, aviation, aerospace, petrochemicals, and defense. The company operates nine facilities located across East, South, and Central India, with five in West Bengal, two in Andhra Pradesh, one in Telangana, and one in Chhattisgarh.

Objects of the issue

The company proposes to utilize the net proceeds from the fresh issue towards funding the following objects:

- Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the
- Setting up of an air separation unit at the Uluberia-II plant with a capacity of 220 TPD; and
- General corporate purposes.

Investment Rationale

Comprehensive product portfolio catering to a diverse customer base minimizes concentration risks

EIG has built strong relationships with several Indian customers across industries over its fifty-year operational history. The company sold its products to 1,829 customers, one of the highest customer counts among gas companies in India, demonstrating a highly diversified customer base and limited concentration risk. By manufacturing a wide variety of industrial gases, EIG serves various sectors, including shipbuilding, glass and steel manufacturing, pharmaceuticals, welding, and fabrication, where the consistent supply of gases is critical to operations. The company supplies various gases, including nitrogen, to major oil and gas companies across multiple sites, as nitrogen is used for increasing well pressure during oil exploration and for purging hydrocarbons in pipelines and tanks during refining. The company also produces ultra-high-purity nitrogen gas for the electronics industry, requiring special technical acumen, and ultra-high-purity oxygen used in laboratories, solar cell manufacturing, and semiconductor applications. EIG actively engages with customers to expand the range of applications for its gases, thereby enhancing customer efficiency and increasing its share of customer spending. It also supplies to sectors such as defense and aerospace, including Indian Air Force bases across East, South, and West India, Eastern Naval Command bases, and various government-owned laboratories. As a part of its project engineering operations, EIG utilizes its extensive technical expertise to design, engineer, supply, install, and commission tonnage ASUs and related infrastructure on a turnkey basis for clients across several sectors.

Strategic locations and a robust distribution network in East and South India enhance supply chain efficiency

EIG has built a strong manufacturing and distribution presence across East and South India, operating nine facilities in West Bengal, Andhra Pradesh, Telangana, and Chhattisgarh. These include three bulk manufacturing ASU plants along with cylinder filling stations, two standalone cylinder filling

24th June 2025 -Offer Period 26th June 2025 Rs. 380 to Rs. 400 Price Band Bid Lot 37 **BSE & NSE** Listing Issue Size (no. 21.3 of shares in mn) Issue Size (Rs. 8.5 in bn) Face Value 2 (Rs.) **Issue Structure**

Retail	35%
	Motilal Oswal
	Investment
DDLM	Advisors Ltd., IIFL
BRLM	Capital Services
	Ltd., JM Financial

50%

15%

Ltd.

Dogiotror	KFIN
Registrar	Technologies Ltd.

Particulars	Pre Issue %	Post Issue %
Promoters and pro- moter group	96.5	81.6
Public	3.5	18.4
Total	100.0	100.0

(Assuming issue subscribed at higher band)

Research Team - 022-61596138

stations, and four onsite plants at customer premises, contributing to its leadership in installed capacity in West Bengal, Andhra Pradesh, and Telangana. With a total oxygen production capacity of 1,250 TPD and the distinction of commissioning Eastern India's first hydrogen electrolyser, the company offers multiple supply modes - onsite, bulk, and packaged - backed by one of the largest fleets of tankers and over 39,560 cylinders. Its facilities in East and South India are strategically located near key pharmaceutical, steel, automotive, railway wagons and locomotive companies, enabling it to service key customers promptly and efficiently. The company has built a robust distribution network supported by its production facilities with the third highest number of transport tankers, cylinders and customer installations in India. To further scale operations, the company has initiated an expansion at its Uluberia facility in West Bengal, with a second plant, and plans two additional projects - one in North India and another in West Bengal - to strengthen its pan-India footprint. It also recently expanded capacity by 170 TPD at a major steel customer's Kharagpur site in January 2025. These expansion plans aim to address rising demand across various sectors and enhance supply chain efficiency nationwide.

Valuation

Ellenbarrie Industrial Gases Ltd. manufactures and supplies industrial gases catering to diverse enduse industries. The company offers services, including project engineering services and also turnkey solutions involving medical gas pipeline systems. In addition, it supplies medical products and equipment to healthcare facilities. The industrial gases market in India is projected to reach USD 1.75 billion by 2028, growing at a CAGR of 7.5%. The industry is directly and significantly influenced by overall economic growth. It is characterized by high customer retention, particularly among large clients, as gases are often supplied directly through pipelines under long-term contracts, typically spanning 15 to 20 years. Given the critical role of industrial gases in manufacturing processes, along with the risks and costs associated with supply disruptions, customers are extremely selective when choosing new suppliers. EIG has effectively addressed these challenges through its long-standing operating history and strong customer relationships, which contribute to stable and recurring revenue. The company benefits from long-term partnerships with three key onsite customers and has established a highly efficient distribution network, supported by its strong manufacturing presence in East and South India. It offers flexible supply options - onsite, bulk, and packaged - based on customer requirements, providing a significant competitive advantage. Its comprehensive product portfolio, catering to diverse industries such as steel, pharmaceuticals and chemicals, healthcare, engineering and infrastructure, railways, aviation, aerospace, petrochemicals, and defense, enhances customer efficiency and minimizes concentration risks. Financially, EIG has delivered a revenue CAGR of 23.4% between FY23 and FY25, while expanding its EBITDA margin from 16.4% to 35.1%, reflecting operational leverage. The company is well-positioned to capitalize on sectoral growth while maintaining profitability and scale. The issue is valued at a P/E ratio of 62.9x at the upper price band based on FY25 earnings, which is relatively cheaper compared to its peers. Considering the above compelling factors, we recommend a "SUBSCRIBE" rating for this issue.

Key Risks

- ⇒ The company supplies products to certain government entities and public sector undertakings through a competitive bidding process where the contracts are awarded on a tender basis. If the company fails to secure these contracts in the future, then it may affect the business, results of operations, cash flows and financial condition of the company. Any change in qualification criteria, unexpected delays, or uncertainties in the tendering process may harm the business. Furthermore, there is a risk of encountering delays in receiving payments from such entities, which could impact the company's cash flows.
- ⇒ The company is subject to strict quality requirements, regular inspections and audits, and sales of its products are dependent on its quality controls and standards. Any failure to comply with quality standards may adversely affect its business prospects and financial performance, including cancellation of existing and future orders.
- ⇒ The business is dependent on its facilities. Four of its facilities are located at the sites of its customers, and any deterioration in their relationship with these customers could adversely affect the business, results of operations, cash flows, and financial condition.

Income Statement (Rs. in millions)

Particulars	FY23	FY24	FY25
Revenue			
Revenue from operations	2,051	2,695	3,125
Total revenue	2,051	2,695	3,125
Expenses			
Cost of Material Consumed	41	38	32
Purchase of Stock-in-Trade	222	534	333
Changes in inventories of finished goods & stock-in-trade	-5	-23	-8
Employee benefit expenses	144	161	228
Power expenses	740	777	749
Impairment loss on financial assets	63	46	21
Other expenses	509	547	672
Total operating expenses	1,715	2,079	2,027
EBITDA	336	615	1,097
Depreciation & amortization expenses	114	100	207
EBIT	222	515	890
Finance costs	35	80	171
Other Income	186	207	359
PBT	373	642	1,078
Tax expense			
Current tax	108	120	191
Prior year taxes	5	0	2
Deferred tax	-21	69	52
Total tax	91	189	245
Net Profit	281	453	833
Diluted EPS	2.2	3.5	6.4
Source: RHP, BP Equities Research			

Source: RHP, BP Equities Research

Cash Flow Statement (Rs. in millions)

Particulars	FY23	FY24	FY25
Cash Flow from operating activities	387	437	43
Cash flow from investing activities	-1,142	-1,217	-569
Cook flow from financing activities	866	675	519
Cash flow from financing activities	000	075	519
Net increase/(decrease) in cash and cash equivalents	111	-105	-7
Cash and cash equivalents at the beginning of the period	3	114	9
Cash and cash equivalents at the end of the period	114	9	2
Source: RHP, BP Equities Research			

Balance Sheet (Rs. in millions)

	,		
Particulars	FY23	FY24	FY25
ASSETS			
Non-Current Assets			
Property, Plant and Equipment	1,815	3,293	3,376
Capital Work-in-Progress	714	4	453
Other intangible assets	3	2	1
Right-of-Use Assets	22	13	12
Financial Assets			
(i) Trade Receivable	0	0	10
(ii) Investments	272	579	1,077
(iii) Loans	0	80	58
(iv) Other financial assets	458	440	1,004
Non-current tax asset (net)	144	85	30
Other non-current assets	185	190	348
Total Non Current assets	3,613	4,686	6,370
Current Assets			
nventories	84	110	142
Financial Assets			
(i) Investments	837	1,118	866
(ii) Trade receivables	394	453	826
(iii) Cash and cash equivalents	114	9	2
(iv) Other bank balances	32	28	28
(v) Loans	194	100	40
(vi) Others financial assets	51	53	43
Other Current Assets	194	167	143
Total Current Assets	1,899	2,039	2,090
Total Assets	5,513	6,725	8,460
EQUITY AND LIABILITIES			
Equity			
Equity Share Capital	65	65	262
Other Equity	3,565	4,033	4,672
Total equity	3,631	4,099	4,934
_iabilities			
Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings	561	950	1,467
(ii) Lease Liabilities	15	7	11
(iii) Other financial liabilities	0	0	20
Provisions	50	56	85
Deferred tax liabilities (net)	188	261	310
Other non-current liabilities	0	0	153
Total Non-Current Liabilities	815	1,273	2,046
Current Liabilities			
Financial Liabilities			
(i) Borrowings	450	819	986
(ii) Lease Liabilities	9	9	2
(iii) Trade payables	176	177	141
(iv) Other Financial Liabilities	156	163	199
Other Current Liabilities	274	185	83
Provisions	3	0	6
Current Tax Liabilities (Net)	0	0	65
Total Current Liabilities	1,067	1,353	1,480
Total Current Elabilities	1,882	2,626	3,526
Total Equity and Liabilities	5,513	6,725	8,460
	3,010	0,120	0,400
Source: RHP, BP Equities Research Institutional Research	BP Equities Pvt. Limited (www.bpwealth.com)		6/2025 4

Research Desk Tel: +91 22 61596138

Institutional Sales Desk Tel: +91 22 61596403/04

Disclaimer Appendix

Analyst (s) holding in the Stock: Nil

Analyst (s) Certification:

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001 Phone- +91 22 6159 6138 Fax-+91 22 6159 6160 Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Wealth Management Pvt. Ltd. CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392